Pangaea Oncology Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2007

Location

Barcelona Spain

Primary Industry

Healthcare

About

Based in Barcelona, Spain, and founded by Rafael Rosell and Javier Rivela in 2007, Pangaea Oncology S.A. operates as a provider of personalized medicine based on genetic analyses. In July 2022, the firm raised EUR 12 million in PIPE funding from investors Electrica del oeste, S.L., Irigen, S.L., Mirling Europe SL and Projecte Asfodel S.L. The firm offers various services such as molecular diagnostics, clinical trials, and biomarker discovery to cancer patients and pharmaceutical as well as biotech clients. Additionally, the company in vitro drug profiling such as MTT proliferation assays, western bolting, and others. Furthermore, the firm offers dx platform validation which includes Ad-hoc R+D for diagnostics companies, Companion diagnostic platform validation, and more. Apart from this, the company provides in vivo pharamacology in animal models if requested by clients. The company plans to use the funding mainly to accelerate its inorganic growth.

Current Investors

Irigen, S.L., Mirling Europe SL, Projecte Asfodel S.L.

Request a demo to show more

Primary Industry

Healthcare

Sub Industries

Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Specialty Pharmaceuticals

Website

www.panoncology.com

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.